Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations
NCT04174352Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by University of Wisconsin–Madison. Primary endpoint: Rate of FES Blockade at each dose level at 6 weeks. Started Oct 2020; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04174352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174352.